The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.

ABSTRACT:

Introduction:

AZD9977 is a novel mineralocorticoid receptor (MR) modulator, which in preclinical studies demonstrated organ protection without affecting aldosterone-regulated urinary electrolyte excretion. However, when tested in humans, using fludrocortisone as an MR agonist, AZD9977 exhibited similar effects on urinary Na⁺/K⁺ ratio as eplerenone. The aim of this study is to understand whether the contradictory results seen in rats and humans are due to the mineralocorticoid used.

Materials and methods:

Rats were treated with single doses of AZD9977 or eplerenone in combination with either aldosterone or fludrocortisone. Urine was collected for five to six hours and total amounts excreted Na⁺ and K⁺ were assessed.

Results:

SUBMITTER: Bamberg K 

PROVIDER: S-EPMC6396052 | biostudies-literature | 2019 Jan-Mar

REPOSITORIES: biostudies-literature